All News
Secukinumab: a human IgG1κ monoclonal antibody that binds to IL-17A
ASAS40: a composite measure including patient global, pain, function, and inflammation
In patients with nr-AxSpA, secukinumab improved ASAS40 through week 52, compared to placebo
Dr. Deodhar #ACR19 @RheumNow https://t.co/yLwt47w2wr
Jonathan Hausmann MD hausmannMD ( View Tweet)
MYTH: Tocilizumab should be reserved for GCA patients whom prednisone has failed
#PearlsAndMyths Dr. John Stone #ACR19 @RheumNow https://t.co/tVrC5XP0ot
Kanika Monga, MD DrKanikaMonga ( View Tweet)
Interesting withdrawal study of tofacitinib in children with JIA showed that drug was better than placebo at preventing disease flares. #pedirheum #ACR19 @RheumNow https://t.co/lHWNJGmmtF
Jonathan Hausmann MD hausmannMD ( View Tweet)
NEW ANCA Associated Vasculitis Guidelines - discussed at #ACR19
1. Rituxan > cytoxan
2. Reduced steroid regimen!
3. Rec against PLEX
4. Rec FOR scheduled RTX over ANCA+B cell guided
5. MTX for limited dx
Well done everyone - very reasonable and evidence based!
@RheumNow https://t.co/oX6qEJDQON
Mike Putman EBRheum ( View Tweet)
NEW Draft Guidelines for EGPA presented at #ACR19 @RheumNow
1. TTE and FFS to guide tx
2. GC plus cytoxan or rituxan for active/severe dx
3. Imuran/MMF/MTX for maintenance after severe dx
4. Mepo for non-severe over csDMARDs
Larger role for RTX than expected, overall reasonable https://t.co/MEb10n5Mzd
Mike Putman EBRheum ( View Tweet)
Video from @gensler_MD on AS and nr-axSpA studies presented at #ACR19 @rheumnow https://t.co/fcn9zCxouU via @YouTube
Philip Robinson philipcrobinson ( View Tweet)
Pregnancy outcome in the DESIR cohort (SpA cohort) #ACR19 @RheumNow https://t.co/PcwR6rrMRw
Philip Robinson philipcrobinson ( View Tweet)
The bit I particularly like out of this: you get *at least* another 10% from going back for more slices from your temporal artery biopsy. Please, sir, may I have some more (slices)?
Reggio Emilia #ACR19 ABST2648 @RheumNow
David Liew drdavidliew ( View Tweet)
The more we know, the more we learn we struggle to predict GCA flares.
Model based on three large GCA cohorts (total n=778) could pick some factors (headaches, limb claudication, aortitis, CRP) but couldn't discriminate well. Other variables important?
#ACR19 ABST2650 @RheumNow
David Liew drdavidliew ( View Tweet)
In case we needed more reassurance: ANCA positivity on IF without a MPO or PR3 rarely leads to ANCA-associated vasculitis.
Maybe if the pathology report had that info attached, it would help reassure our generalist colleagues?
@ShaareZedekMed #ACR19 ABST2642 @RheumNow
David Liew drdavidliew ( View Tweet)
MGUS is really common in the general population. Therefore, it’s going to be really common in our rheumatic patient population
#acr19 https://t.co/9HIWvDm20n
Dr Irwin Lim _connectedcare ( View Tweet)
Here’s the risk stratification for MGUS
#ACR19 @rheumnow 5T064 https://t.co/fKeJu8n5DI
Dr Irwin Lim _connectedcare ( View Tweet)
Do you routinely consider ACPA status in your choice of Biologic MOA?
Olga Petryna DrPetryna ( View Tweet)
#ACR19 @rheumnow L20 head-to-head IXE vs ADA PSA 52wk trial: IXE shows significantly ⬆️ response than ADA for simultaneous ACR50 + PASI100 through Wk 52.TEAEs in 73.9% IXE &68.6% ADA pts. sAEs in 4.2% IXE&12.4% ADA pts, and d/c 2/2 AEs in 4.2% IXE & 7.4% ADApts; no deaths https://t.co/WeGdmu0vh6
Olga Petryna DrPetryna ( View Tweet)
#ACR19 RITAZAREM RCT rituxan vs imuran, AAV maintenance
RTX superior to imuran w/HR 0.36 and relapse rate at 24 months (13% vs 38% imuran, NNT=4). Hypogam risk only 4% higher vs imuran (NNH~25) and non-severe infections similar
Supports guideline recs from this AM!
@RheumNow https://t.co/m9FkJ7d7I9
Mike Putman EBRheum ( View Tweet)
#ACR19 @RheumNow
FINCH1 results for filgotinib in RA w/MTX inadequate response
Good efficacy over PLBO for ACR50 at 24 wks (NNT~4), somewhat less impressive than UPA against TNF (NNT~20, not superior)
Lower rates of HSV! Also, like UPA there is (as yet) no VTE signal https://t.co/1HjFgfXvlX
Mike Putman EBRheum ( View Tweet)
J Stone IgG4-RD pearl: If elevated at baseline the serum IgG4 is a good biomarker for IgG4-RD.
If very high, IgG4, can be a marker for recurrent disease. Hypocomplementemia implies renal involvement. #ACR2018 @RheumNow
Maeve Gamble MaeveGamble ( View Tweet)
Ixekizumab is a high-affinity monoclonal antibody against interleukin-17A.
In patients with psoriatic arthritis, ixekizumab was better than adalimumab in treating skin disease (PASI 100).
Similar improvements in joint disease (ACR20/50/70).
Dr. Josef Smolen #ACR19 @RheumNow https://t.co/BriY8o10Hq
Jonathan Hausmann MD hausmannMD ( View Tweet)
In patients with Sjogren's, Ianalumab, a dual-mode of action biologic combining BAFF receptor inhibition with B cell depletion, showed significant response in ESSDAI, a disease activity index, but did not seem to improve most PROs such as fatigue #ACR19 @RheumNow https://t.co/l5UFwOjt2C
Jonathan Hausmann MD hausmannMD ( View Tweet)
Abstr# 2440: Strong association between psoriatic arthritis and osteoporosis (45%) and osteopenia (13%). A good reminder to screen these patients to avoid complications of these additional comorbidities. #ACR19 @RheumNow https://t.co/0RvJtYCYJl
Dr. Paul Sufka psufka ( View Tweet)